Anti-VEGF Therapy - Managing Challenging Case Scenarios

Anti-VEGF Therapy - Managing Challenging Case Scenarios

Saved in:

Bibliographic Details
Main Authors:	Anand Rajendran, Philip J Rosenfeld, Srinivas Sadda, Dhananjay Shukla, Mahesh Shanmugam
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2014-10-01
Series:	Delhi Journal of Ophthalmology
Online Access:	https://journals.lww.com/10.7869/djo.93
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Anti-VEGF Therapy and the Retina: An Update
by: Vikas Tah, et al.
Published: (2015-01-01)

Pharmacological Analysis of Resistance to Anti-VEGF Therapy
by: M. V. Budzinskaya, et al.
Published: (2019-01-01)

Anti-VEGF for the Management of Diabetic Macular Edema
by: Francisco Rosa Stefanini, et al.
Published: (2014-01-01)

Results of anti-VEGF therapy in patients with uveal melanoma
by: V.A. Yarovaya, et al.
Published: (2024-03-01)

Impact of photodynamic therapy combined with Anti-VEGF vs. Anti-VEGF monotherapy on choriocapillaris vessel density in polypoidal choroidal vasculopathy
by: Po-Chin Kuo, et al.
Published: (2025-04-01)

Role of Anti VEGF Agent in Management of Primary Pterygium
by: Abhinav Singh, et al.
Published: (2018-10-01)

Clinical Course and Results of Anti-VEGF Therapy of Retinopathy of Prematurity
by: L. A. Katargina, et al.
Published: (2021-04-01)

The Application of OCTA in Assessment of Anti-VEGF Therapy for Idiopathic Choroidal Neovascularization
by: Qin Chen, et al.
Published: (2016-01-01)

Management of Recurrent Tube Exposure in A Challenging Scenario
by: Meena Menon, et al.
Published: (2017-04-01)

The Effects of VEGF Signal Pathway on Etiopathogenesis and AntiVEGF Treatments in Childhood Cancers
by: Ali Kazdal, et al.
Published: (2023-09-01)

Targeting retinal angiogenesis: sex differences in adverse reactions to anti-VEGF therapies
by: Eleonora Castellana, et al.
Published: (2025-07-01)

A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
by: Kiran Turaka
Published: (2014-04-01)

Metabolomics analysis uncovers metabolic changes and remodeling of anti-VEGF therapy on macular edema
by: Congcong Yan, et al.
Published: (2025-07-01)

Next-Generation Long-Acting Anti-VEGF Therapies for the Treatment of Diabetic Macular Edema
by: Piotr Rzyczniok, et al.
Published: (2025-04-01)

THE ROLE OF ANTI-VEGF THERAPY IN IMPROVING THE EFFICACY OF SURGICAL TREATMENT OF SECONDARY NEOVASCULAR GLAUCOMA
by: Uliana Sydorchuk, et al.
Published: (2024-10-01)

Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations
by: Sanjay Sharma, et al.
Published: (2025-01-01)

Anti-VEGF combined with fufang xueshuangtong versus anti-VEGF monotherapy for wet age-related macular degeneration: A meta-analysis
by: Tingke Xie, et al.
Published: (2025-06-01)

Systemic Effects of Intravitreal Anti-VEGF Therapy: A Review of Safety across Organ Systems
by: Mousumi Banerjee, et al.
Published: (2025-06-01)

Refractive errors in premature infants with retinopathy of prematurity after anti-vascular endothelial growth factor (anti-VEGF) therapy
by: Vujanović Milena S., et al.
Published: (2017-01-01)

Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
by: Shivi Agrawal, et al.
Published: (2013-01-01)

Anti-VEGF agents in the treatment of diabetic macular edema
by: Vladimir Iosifovich Konenkov, et al.
Published: (2013-12-01)

THE FIRST EXPERIENCE OF USING ANTI-VEGF THERAPY PRIOR TO CATARACT SURGERY IN PATIENTS WITH DIABETIC MACULAR EDEMA
by: N. A. Malysheva
Published: (2018-10-01)

Role of S1PR1 in VEGF-exosomes mediated resistance of hepatocellular carcinoma to anti-angiogenesis therapy
by: Xinghong Yao, et al.
Published: (2025-07-01)

Long-Term Outcomes of Nonadherence to Anti-VEGF Therapy in Advanced Neovascular Age-Related Macular Degeneration
by: A. N. Kulikov, et al.
Published: (2022-10-01)

A machine learning model for predicting anatomical response to Anti-VEGF therapy in diabetic macular edema
by: Wenrui Lu, et al.
Published: (2025-05-01)

Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion
by: A. B. Galimova, et al.
Published: (2023-12-01)

Development and validation of CNN-MLP models for predicting anti-VEGF therapy outcomes in diabetic macular edema
by: Xiangjie Leng, et al.
Published: (2024-12-01)

Polypoidal Choroidal Vasculopathy Treatment: Photodynamic Therapy, Anti-VEGF Monotherapy or Combination. Review of Clinical Studies
by: E. K. Pedanova, et al.
Published: (2019-06-01)

Management of Challenging Psoriasis Clinical Scenarios
by: Linda Stein Gold, et al.
Published: (2025-04-01)

Efficacy and safety of intravitreal anti-VEGF for myopic choroidal neovascularization
by: Jing-Yao Liu, et al.
Published: (2025-09-01)

Management and safety of same day bilateral intravitreal anti-VEGF injections in a treat-and-extend regimen
by: Christina Plasencia, et al.
Published: (2025-08-01)

The Efficacy of Anti-VEGF Therapy for Putative or Visible CNV in Central Serous Chorioretinopathy by Optical Coherence Tomography Angiography
by: Yumeng Zhang, et al.
Published: (2022-01-01)

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
by: R. R. Fayzrakhmanov
Published: (2019-06-01)

Use-case scenarios for an anti-Cryptosporidium therapeutic.
by: Paul G Ashigbie, et al.
Published: (2021-03-01)

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
by: Young Gun Park, et al.
Published: (2012-01-01)

Renal Involvement in Preeclampsia: Similarities to VEGF Ablation Therapy
by: Janina Müller-Deile, et al.
Published: (2011-01-01)

Efficacy of dexamethasone implant in the management of chronic central serous chorioretinopathy without choroidal neovascularization
by: Umesh Chandra Behera, et al.
Published: (2025-01-01)

Phacoemulsification surgery in patients with diabetic macular edema: should intravitreal anti-VEGF therapy be performed before or simultaneously with surgery?
by: Yusuf Ziya Güven, et al.
Published: (2025-04-01)

Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 1
by: E. V. Bobykin, et al.
Published: (2022-09-01)

Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 2.
by: E. V. Bobykin, et al.
Published: (2022-12-01)